<DOC>
	<DOCNO>NCT00752180</DOCNO>
	<brief_summary>The aim trial demonstrate bioequivalence Wosulin R Actrapid regard total maximum serum insulin concentration .</brief_summary>
	<brief_title>Comparative Glucose Clamp Study Wockhardt 's Insulin Human Regular Injection Actrapid , Type 1 Diabetics</brief_title>
	<detailed_description>The purpose study test bioequivalence base pharmacokinetic parameter Cmax AUC0-12h two recombinant soluble human insulin preparation . The study also compare pharmacokinetic parameter pharmacodynamic profile well assess safety local tolerability two insulin preparation type 1 diabetic .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male female subject type 1 diabetes mellitus Age 18 45 year ( inclusive ) Insulin treatment least 12 month screen visit Daily basal insulin requirement 0.2 0.6 IU/kg/day ( inclusive ) current total daily insulin dose le 1.2 IU/kg/day . Body Mass Index ( BMI ) 18.0 35.0 kg/m2 HbA1c le equal 10.0 % Fasting Cpeptide &lt; 0.4 nmol/L Nonsmoker , nicotine consumption least one year . Subjects consider generally healthy , except underlie diabetes mellitus relate morbidity ( well control hypertension dyslipidemia ) Signed date informed consent obtain trialrelated activity Previous participation trial clinical trial within 30 day dose 5 halflives investigational drug , whichever longer . If half life investigational drug unknown , previous participation clinical trial within 3 month dose . Pregnant , breastfeed intention become pregnant use adequate contraceptive measure ( define intrauterine device place least 3 month , double barrier contraception , sterilization abstinence , oral contraceptive pill , take without difficulty least 3 month , approve hormonal implant ) . Clinically significant abnormal hematology biochemistry screen test , judge Investigator . In particular , subject elevate liver enzymes ( AST ALT &gt; 2 time upper limit normal ) impair renal function allow enter trial . Any serious systemic infectious disease four week prior first dose test drug , History illness , opinion Investigator , might confound result trial pose risk administer trial drug subject . In particular , subject significant cardiovascular disease , anemia hemoglobinopathy allow enter trial . Cardiac problem define : decompensated heart failure ( NYHA class III IV ) time and/or angina pectoris and/or myocardial infarction within last 12 month . Uncontrolled hypertension Subjects screening , 5 minute rest , supine blood pressure outside range 90140 mmHg systolic 5090 mmHg diastolic , pulse rate outside range 40 90 beat per minute , require two antihypertensive medication . Severe neuropathy ( particular autonomic neuropathy ) , retinopathy maculopathy Clinically significant abnormal ECG screen Recurrent major hypoglycemia hypoglycemic unawareness judge investigator hospitalization diabetic ketoacidosis 6 month precede screen visit . History alcohol drug abuse past five year and/or positive test drug abuse screen . Positive test hepatitis B C HIV Any systemic treatment drug know interfere glucose metabolism systemic corticoid , nonselective betablockers , thyroid hormone monoamine oxidase inhibitor within 3 month prior first dose visit . Use drug may interfere interpretation trial result know cause clinically relevant interference insulin action , glucose utilization recovery hypoglycemia Blood donation 500 mL within last 12 week History multiple and/or severe allergy drug food history severe anaphylactic reaction Known suspect allergy trial product relate product Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>type 1 diabetic</keyword>
	<keyword>recombinant human insulin</keyword>
</DOC>